Future of imaging science depends on risk takers
Radiologists need to become great risk takers and follow clinical science's move toward systems biology or become irrelevant, according to Dr. Elias Zerhouni, director of the National Institutes of Health.
Radiologists need to become great risk takers and follow clinical science's move toward systems biology or become irrelevant, according to Dr. Elias Zerhouni, director of the National Institutes of Health.
Imagers need to replace the current imaging approach to understand complex disease mechanisms, such as inflammation or apoptosis, rather than simply specific conditions, like arthritis or cancer. That means moving down the angstrom scale to resolve complex macromolecular structures, Zerhouni said.
Radiologists should develop biomarkers to assist in the study of treatments for long-term chronic diseases and get involved in image-guided intervention and microsampling for disease characterization, he said.
Zerhouni spoke during a session on the future of biomedical imaging and imaging research at the European Congress of Radiology. The NIH will invest about $1 billion in 2007 in projects with non-U.S. partners.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
